Site icon Market Globalist

CELC Stock Soared Nearly 51%. What Triggered The Rise?

AMHC

AMHC

Starting the day at $22.08, the clinical-stage biotechnology company Celcuity Inc. (NASDAQ: CELC) watched its intraday high rise to $24.25 in last session. During Friday’s trading session, Celcuity stock also registered a low of $19.04 but concluded the day at $21.60 rising 50.94%.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

On Friday, CELC stock recorded a higher trading volume than its average daily volume in the past 30 days. Compared to the average daily volume of 288.52K, CELC stock traded on Friday for 15.8M shares. Due to a phase-1b trial for cancer treatment which provided encouraging data, the CELC stock rose on the day.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Read More

What were the findings of the study?

Cercuity is a clinical-stage biotechnology company pursuing a comprehensive approach to companion diagnostic and therapeutic intervention for cancer patients. In form of CELsignia, CELC has created a diagnostic platform that uniquely identifies new groups of patients likely to benefit from targeted therapies using live patient tumor cells. A CELsignia CDx can help make existing targeted therapies more potent in new applications.

The preliminary data of an ongoing Phase 1b clinical trial conducted by Celcuity on 103 patients was announced on Friday.

CELC has achieved what?

This Phase 1b preliminary trial is showing promising results for GEDATOLISIB in patients with breast cancer. Considering the importance of addressing resistance to endocrine therapy, the CELC-researched study presented the best response rate and observed tolerability profile to date. Develop a therapeutic like gedatolisib will allow Celcuity (CELC) to more fully utilize its CELsigia platform and its cellular analysis capabilities.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Exit mobile version